<DOC>
	<DOCNO>NCT00283101</DOCNO>
	<brief_summary>This open-label , dose-escalation study determine tolerability , safety profile , antitumor activity SGN-40 patient CLL . All patient receive dose escalation first two week regardless cohort designation .</brief_summary>
	<brief_title>A Safety Study Patients With Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>A minimum three patient enter dose-level cohort five week . Escalation next cohort occur three patient receive least one infusion high schedule dose level , least one patient complete entire five week dosing schedule . Cohorts enrol maximal dose level 3 , 4 , 6 , 8 mg/kg/week . Initial therapy last 5 week . Responding patient receive additional infusion every two week x 4 maximal dose specific cohort .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>1 . Patients must histologic diagnosis CLL define WHO criterion exhibit active disease require treatment per NCI work group CLL . 2 . Patients must fresh tumor specimen available ( peripheral blood bone marrow ) flow cytometry evaluation ( e.g . CD40 , CD38 , CD20 , CD19 , CD5 ) .For phase 2 portion study , CD40 expression malignant cell must confirm prior registration . 3 . Patients must relapse receive least one fludarabine contain regimen equivalent purine analog . At study start patient must least 8 week 5 plasma halflives ( whichever great ) prior chemotherapy/radiation/investigational agent , 8 week prior antibody therapy 6 month autologous stem cell transplant . 4 . Patients must ECOG performance status ≤ 2 life expectancy &gt; 3 month . 5 . Patients must follow required baseline laboratory data : Platelet count ≥ 50,000/mm3 ( may maintain transfusion ) Hemoglobin ≥ 7.5 g/dL ( may maintain transfusion growth factor ) Absolute neutrophil count ≥ 1,000/mm3 ( may maintain growth factor ) ALT/AST ≤ 2.0 time ULN Total bilirubin ≤ 2.0 time ULN ( unless relate hemolysis ) Creatinine &lt; 2.0 time ULN 6 . Females childbearing potential must negative BhCG pregnancy test result within 3 day prior first dose must agree use effective contraceptive method course study 6 month follow last dose study drug . 7 . If deep venous thrombosis vascular event require medical surgical intervention past year , patient must either : ) stable dose anticoagulant therapy ( i.e. , Coumadin and/or Heparin ) least three week b ) complete anticoagulant therapy least three month prior registration radiographic confirmation thrombosis resolve . Prophylactic anticoagulant therapy indwell catheter acceptable . 8 . Patients must least 18 year age . 9 . Patients must available periodic blood sampling , studyrelated assessment , management toxicity treat institution . 10 . Patients must give write informed consent . A copy sign informed consent form retain treating institution . 1 . Patients treat previously antiCD40 antibody . 2 . Patients document history within 6 month registration cerebral vascular event ( stroke TIA ) , unstable angina , myocardial infarction . 3 . Patients active CNS leptomeningeal disease . 4 . Patients receive allogeneic stem cell transplant . 5 . Patients major surgery within four week prior enrollment . 6 . Patients know hypersensitivity recombinant proteins excipient contain drug formulation . 7 . Patients history another primary malignancy remission least 5 year ( nonmelanoma skin cancer cervical carcinoma situ biopsy squamous intraepithelial lesion PAP smear exempt five year limit ) . 8 . Patients systemic viral , bacterial , fungal infection require antibiotic therapy within four week prior enrollment . Prophylactic antibiotic antiviral therapy permit prior registration require study period ( e.g . Bactrim , acyclovir ) . 9 . Patients know HIV , hepatitis B ( surface antigen expression ) , active hepatitis C infection . 10 . Patients systemic steroid stable daily dose four week immediately prior first dose SGN40 . Maximum steroid dose 10 mg prednisone per day equivalent . 11 . Patients history migraine severe headache require medical therapy ( occasional acetaminophen , aspirin , nonsteroidal antiinflammatory drug ) within 12 month enrollment . 12 . Patients pregnant breastfeeding . 13 . Patients serious underlying medical condition would impair ability receive tolerate plan treatment . 14 . Patients dementia alter mental status would preclude understanding and/or rendering inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Antigens , CD40</keyword>
	<keyword>Antibody , Monoclonal</keyword>
	<keyword>Leukemia , Lymphocytic , Chronic , B-Cell</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Immunoproliferatic Disorders</keyword>
	<keyword>Lymphatic Diseases</keyword>
	<keyword>Lymphoproliferative Disorders</keyword>
	<keyword>Leukemia</keyword>
</DOC>